Simulations Plus Sets Date For 2nd Quarter 2012 Earnings Release And Conference Call

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2012 fiscal year, ended February 29, 2012, with the U.S. Securities and Exchange Commission today, Monday, April 9, 2012. Chairman and Chief Executive Officer Walt Woltosz will host a conference call to discuss the Company’s performance on Tuesday, April 10, at 1:15 p.m. PT / 4:15 p.m. ET.

The conference call will be webcast live and may be accessed by first registering at the following website: https://www2.gotomeeting.com/register/125724146. Upon registering, you will receive a confirmation e-mail with a unique link and instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (914) 339-0024, and enter access code 323-956-377.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.

Copyright Business Wire 2010

If you liked this article you might like

Market Can't Sustain Upside Push

Market Can't Sustain Upside Push

10 High-Growth Health Care Stocks to Buy Now

10 High-Growth Health Care Stocks to Buy Now

Mid-Cap A+ Rated Stocks That Pay High Dividends

Mid-Cap A+ Rated Stocks That Pay High Dividends

12 'A+' Rated Stocks With Great Growth Potential and High Return on Invested Capital

12 'A+' Rated Stocks With Great Growth Potential and High Return on Invested Capital

20 A+ Rated Mid-Cap Growth Stocks

20 A+ Rated Mid-Cap Growth Stocks